-
How will the UK-US pharma deal affect drug prices?
The agreement aims to facilitate more flexible pricing models, including outcome-based pricing and ending rebate schemes. Eli Lilly has indicated it might resume UK investments if reforms are agreed, which could lead to more innovative and potentially more affordable medicines for patients.
-
What does mutual recognition of medical device approvals mean?
Mutual recognition allows both countries to accept each other's medical device approvals, speeding up access to new medical technologies and reducing regulatory delays. This can improve patient care and foster innovation in medical devices.
-
Will this deal lead to better access to medicines in the UK?
By increasing NHS drug expenditure and streamlining approval processes, the deal aims to improve access to new medicines. However, the impact will depend on how reforms are implemented and negotiations with pharmaceutical companies.
-
How might this cooperation influence future UK-US healthcare policies?
This deal could set a precedent for deeper collaboration on healthcare regulation, drug development, and pricing strategies, potentially shaping policies that balance innovation, affordability, and public health priorities.
-
What are the risks of increased pharmaceutical cooperation?
Potential risks include higher drug prices if negotiations favor industry interests, or regulatory challenges if mutual recognition bypasses thorough safety assessments. Careful oversight will be essential to ensure public health is protected.